In a study published recently in Nature Communications, the developers reported reconfiguring an earlier serological assay that they had developed based on a tri-part split-NanoLuc, a novel bioluminescence platform, to detect antibodies that bind to the SARS-CoV-2 spike protein.
Experts highlight better government-industry coordination as key to ramping testing in future pandemics but question if recent progress will prove enduring.